C. Oliver Kappe received his diploma- (1989) and his doctoral (1992) degrees in organic chemistry from the University of Graz where he worked with Professor Gert Kollenz on cycloaddition and rearrangement reactions of acylketenes. After periods of postdoctoral research work on reactive intermediates and matrix isolation spectroscopy with Professor Curt Wentrup at the University of Queensland in Brisbane, Australia (1993- 1994) and on synthetic methodology/ alkaloid synthesis with Professor Albert Padwa at Emory University in Atlanta, USA (1994-1996), he moved back to the University of Graz in 1996 to start his independent academic career. He obtained his “Habilitation” in 1998 in organic chemistry and was appointed Associate Professor in 1999. Since 2011 he holds the position of Professor of “Technology of Organic Synthesis” (Organische Synthesetechnologie) at the University of Graz. He has spent time as visiting scientist/professor at e.g. the Scripps Research Institute (La Jolla, USA, Professor K. Barry Sharpless, 2003), the Toyko Institute of Technology (Toyko, Japan, Professor T. Takahashi, 2008), the University of Sassari (Sassari, Italy, 2008), the Sanford-Burnham Institute for Medical Research (Orlando, USA, 2010) and the Federal University of Rio de Janeiro (Rio de Janeiro, Brazil, 2013). The co-author of more than 300 publications, his main research interests have in the past focused on multicomponent reactions, combinatorial chemistry and the synthesis of biologically active heterocycles. More recently his research group has focused on the use of enabling and process intensification technologies for synthetic chemistry, including microwave and continuous flow processing. For his innovative work in microwave chemistry he received the 2004 Prous Science Award from the European Federation for Medicinal Chemistry and the 2010 Houska Prize (€ 100.000) in addition to a number of other awards.

Tim Jamison was born in San Jose, CA and grew up in neighboring Los Gatos, CA. He received his undergraduate education at the University of California, Berkeley. A six-month research assistantship at ICI Americas in Richmond, CA under the mentorship of Dr. William G. Haag was his first experience in chemistry research. Upon returning to Berkeley, he joined the laboratory of Prof. Henry Rapoport and conducted undergraduate research in his group for nearly three years, the majority of which was under the tutelage of William D. Lubell (now at the University of Montreal). A Fulbright Scholarship supported ten months of research in Prof. Steven A. Benner’s laboratories at the ETH in Zürich, Switzerland, and thereafter he completed his PhD studies at Harvard University with Prof. Stuart L. Schreiber. He then moved to the laboratory of Prof. Eric N. Jacobsen at Harvard University, where he was a Damon Runyon-Walter Winchell postdoctoral fellow. In July 1999, he began his independent career at MIT, where his research program focuses on the development of new methods of organic synthesis and their implementation in the total synthesis of natural products.

Andrew Brusoe currently serves as a Principal Scientist of Process Research in the Chemical Development department at Boehringer Ingelheim Pharmaceuticals in Ridgefield, CT. He earned his B.A from Albion College before becoming a founding member of the Alexanian group at UNC Chapel Hill in 2008, where his focus was primarily on Rhodium-catalyzed [2+2+2] cycloadditions. After completing his Ph.D. in 2013, hejoined UC Berkeley as a postdoc in the Hartwig group, contributing to projects involving Pd-catalyzed arylation of fluorinated amines, mechanistic studies of the Ullman condensation, and fluorodecarboxylation for the synthesis of trifluoromethyl ethers. In 2015, he transitioned to the flow chemistry group at Boehringer, specializing in developing flow processes to support colleagues in Ridgefield, CT, and Biberach, Germany. In 2020, Andrew assumed a role in process research, where he now oversees drug substance synthesis campaigns. His responsibilities encompass chemical process development and supporting medicinal chemistry, pre-clinical toxicology, and Phase I and II studies.

Joel Calvin received his BS in Biochemistry from Indiana University, Bloomington in 1990.  He obtained a position at Reilly Industries where he worked on optimizing the catalytic synthesis of pyridine and pyridine derivatives using fluidized beds as well as batch processes.  Joel obtained his Masters in Organic Chemistry from Purdue University at Indianapolis in 1994.  He joined Eli Lilly and Company in 2000 and began working on flow chemistry in 2008 and has been involved with several flow processes operated in manufacturing.

Eva Deitmann studied Chemical Engineering (B. Sc., M. Sc.) at the Universities of Applied Sciences in Emden and Münster, Germany. She is a PhD student at Ulm University, Germany, and a scientific researcher in the Flow Chemistry group at the Fraunhofer Institute for Microengineering and Microsystems IMM in Mainz, Germany. Her research activities focus on reactive intermediates, especially the synthesis and direct conversion of Grignard reagents and the transfer from batch synthesis to continuous processes.

SUMMARY

10+ years of experience as a process safety engineer and process engineering lead in pharmaceutical drug development.
Effectively scaled-up processes in multiple projects both in batch and flow mode across portfolios by developing robust solutions and meet tight timelines.
Coordinated critical activities with cross-functional teams in India and in USA.
Hands-on experience with various analytical techniques and their interpretation.
Excellent written and oral skills along with presentation skills.

KEY SKILLS

Process R&D and Scale-up, PAT tools, Technology Transfer, Process Safety, Dynochem, Continuous processing, cGMP, API Crystallization, Green chemistry

Education                  

 Ph.D.: Vellore Institute of Technology, Vellore, India

Thesis Title: Synthesis and antibacterial activity of quinoline piperazine hybrids

Employment             

Anthem Biosciences Pvt. Ltd.

Head – Process & New Technology Development

Associated since April 2007

Joined the company since its inception. Responsible for setting up the chemistry labs and the research teams. Developed a team of 300 chemists in a span of 15+ years, with skill sets in diverse areas in chemistry      

Syngene International Pvt. Ltd., Bangalore, India.

Scientist – April 2001 to March 2007

Joined Syngene post M.Phil graduation from University of Madras.  Associated with Dr. Sathyashankar during the tenure at Syngene.  Handled various projects ranging from milligram scale to scale up. 

Publications               

1. Indian Patent Application No.: 202141034236 Dated : 29-07-2021

2. Indian Patent Application No.: 202241038575 Dated : 05-07-2022
3. Royal Society of Chemistry, Novel quinoline-piperazine hydrids:The design, synthesis and evaluation of antimicrobial and antituberculosis properties; DOI:10.1039/D2MD00260D

Honors                  

CSIR-UGC Fellowship, 2000-2001

Key Features

Introduction:

After completing post-graduation course in Chemistry at Madras University in 2001. Joined Syngene International Pvt. Ltd. as trainee scientist and associated with Syngene until March 2007. In April 2007 joined Anthem Biosciences as scientist and rose to Head – Process & New Technology in a span of 15 years.  Built a good cohesive group of 300 chemist with diverse chemistry skills.

Hansjoerg Lehmann received his PhD in 1991 in organic chemistry and started his industrial career in 1992 at Aventis in Germany as a Lab Head in agrochemical research. In 1997 he moved to the chemical process development as a technical project leader. In 2003, he joined the Prep-Labs of Novartis Switzerland where he was responsible for synthesis of intermediates and APIs on a 20 – 500 g scale for medicinal chemistry. For more than 15 years, he’s been active as an expert for lab automation and continuous flow chemistry, who transferred many projects for scale-up from research to chemical development.

Job position:

Scientist – Chemical Engineering, Process Research Laboratory, Iwata Factory, Takasago International Corporation, Japan

Education and career:

Kyoto University (2006-2015), BEng, MEng and Ph.D in Engineering, Chemical Engineering

Takasago International Corporation (2015-present), Scientist – Chemical Engineering

Dr. Fridtjof Schröder is Research Fellow at the Science & Technology Department at the Zürich Innovation Center of Givaudan in Switzerland.

1993 he completed his studies at the Freie Universität Berlin with a PhD in synthetic organic chemistry (unnatural amino acids for peptide hormones) under the supervision of Prof. J. Mulzer. After two postdoctoral years in the group of Prof. W. Oppolzer (organometallic chemistry) at the Université de Genève, another stay with Prof. G. Quinkert and Prof. A. Eschenmoser at the Goethe-Universität in Frankfurt (prebiotic RNA) and two years at Cilag AG Switzerland (pharmaceutical chemistry for Johnson & Johnson) he joined Givaudan in 1999.

His current process research activities are in the areas of homogeneous catalysis, cyclopropanation, flow chemistry and photochemistry for the development of fragrance ingredients.

He published more than 50 articles and patents and received the Sandmeyer award together with colleagues from Givaudan for outstanding work in the field of industrial and applied chemistry in 2023. He presented process highlights at numerous Scientific Update and other conferences.

Dr. William (Bill) J. Smith III, is a Director of Chemical Development at Asymchem where he is focused on process development and project management for large pharmaceutical as well as biotech companies. His career experience of more than 30 years spans Drug Discovery and Process R&D from Preclinical through Phase III. Before entering the pharmaceutical industry, Bill earned a BA in Chemistry from Rutgers University and a PhD in Organic Chemistry from the University of Michigan. Bill’s expertise resides in asymmetric synthesis, total synthesis, and synthetic methodology.

Steve studied at the University of York, UK, completing his MChem degree in 2006 and MSc in Liquid Crystals and Nanoscience in 2007. This was followed by an EPSRC funded PhD in heterogeneous PGM catalysts, completed in 2012 at the University of York. He then joined Syngenta as a Physical Chemist for 2 years researching co-crystals of APIs.

In 2014, Steve joined Johnson Matthey as a Development Chemist, focusing on developing new industrial heterogeneous PGM catalysts for petrochemical and bio-renewable applications from inception, through scale-up and manufacture.

In his current role as Product Specialist, Steve is responsible for a portfolio of heterogeneous catalysts, supporting the development and manufacture of new and existing catalysts within the business.

Dr. Zheng Zhao received his PhD in Chemical Engineering with Dr. Resasco at The University of Oklahoma focusing on heterogenous catalyst design and strategies for biomass upgrading. Before joining Pfizer, he worked at Amneal Pharmaceuticals as a formulation scientist on the Solid Oral Dosage drug product research and process development. Currently he is a Senior Chemical Engineering at Pfizer Flexible API Supply Technology (FAST) located in Groton CT. He has been developing flow platforms for API synthesis and scale up studies using packed bed reactors, which enable metal catalysts, metal oxides and biocatalysts for a wide range of reactions.